A review on diabetic foot infections and other soft tissue infections with emphasis on outpatient infusion therapy is presented here as a Medscape CME activity. It contains a world of information on the practical and administrative aspects of outpatient parenteral antibiotic therapy.
Given the recent controversy about Medscape CME I’ll offer my take regarding any commercial bias for this activity and others from Medscape that I link to. This activity was supported by Wyeth pharmaceuticals, the makers of Tygacil. Although listed among alternatives for outpatient infusion therapy for soft tissue infections, Tygacil was given no favorable comments over other alternatives. If anything the article was somewhat favorable to daptomycin (Cubicin) which is not a product of the sponsoring company. The favorable comments regarding daptomycin appropriately reflect new concerning evidence about vancomycin and infusion related concerns. This activity was scientifically rigorous and free of commercial bias.